Advances in treatment and prevention of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in children.

Abstract

In recent years, there has been a significant increase in reported cases of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in pediatric patients, and its standardized treatment and effective prevention have increasingly attracted clinical attention. This article reviews the latest treatment approach for pulmonary thromboembolism complicated by Mycoplasma pneumoniae pneumonia in children, including anticoagulant therapy, systemic thrombolytic therapy, interventional therapy, and surgical therapy. Meanwhile, progress in research on the risk factors of this condition is also reviewed, aiming to provide new directions for future preventive studies. IMPACT: While several reviews have addressed the clinical characteristics of pulmonary thromboembolism (PTE) associated with Mycoplasma Pneumoniae pneumonia (MPP) in pediatric patients, there remains a lack of comprehensive syntheses focusing specifically on treatment and prevention. This review provides an integrated analysis of the latest evidence on treatment strategies over the past 5 years, facilitating informed clinical decision-making. Moreover, this review is the first to systematically map the studies on the risk factors of PTE induced by MPP, directly informing the directions of future preventive studies.